AdvaMed Plays Tariff Chess
The medical device industry continues to face uncertainty as shifting tariff policies threaten access to critical technologies and long-term market stability. In response, AdvaMed has taken a strategic approach to tariff advocacy in 2025, focusing on predictability, planning, and growth rather than short-term reactions.
AdvaMed plays tariff chess by advancing a zero-for-zero tariff model designed to support innovation, strengthen global competitiveness, and protect patient access to lifesaving medical technologies. This approach emphasizes stability across global medtech markets while enabling continued manufacturing and investment in the United States.
Scott Whitaker, President and CEO of AdvaMed®, has emphasized that while the administration’s tariff strategy has often been reactive and broad in scope, AdvaMed’s focus remains on long-term policy solutions. By advocating for manageable and predictable tariff levels, AdvaMed is helping medtech companies innovate, grow, and plan with confidence in an increasingly complex global trade environment.